MX2022011155A - Inmunización activa de refuerzo contra tétanos, difteria y tosferina. - Google Patents

Inmunización activa de refuerzo contra tétanos, difteria y tosferina.

Info

Publication number
MX2022011155A
MX2022011155A MX2022011155A MX2022011155A MX2022011155A MX 2022011155 A MX2022011155 A MX 2022011155A MX 2022011155 A MX2022011155 A MX 2022011155A MX 2022011155 A MX2022011155 A MX 2022011155A MX 2022011155 A MX2022011155 A MX 2022011155A
Authority
MX
Mexico
Prior art keywords
diphtheria
pertussis
booster immunization
immunization against
immunogenic compositions
Prior art date
Application number
MX2022011155A
Other languages
English (en)
Inventor
Robert L Coffman
Robert S Janssen
John D Campbell
David Novack
Randall N Hyer
Martin Gohlke
Maureen Urban
Sunil Gairola
Umesh Shaligram
Manish Gautum
Harish Rao
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of MX2022011155A publication Critical patent/MX2022011155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se refiere a composiciones inmunogénicas que comprenden antígenos de tétanos, difteria y tosferina acelular (Tdap), y un agonista del receptor tipo toll 9 (TLR9), tal como un oligonucleótido que comprende un motivo de citidina-fosfo-guanosina (CpG) no metilado. Las composiciones inmunogénicas pueden comprender además un adyuvante de sal de aluminio en el que se adsorben los antígenos Tdap. Las composiciones inmunogénicas son adecuadas para la inmunización activa de refuerzo contra tétanos, difteria y tosferina en un individuo en necesidad de las mismas.
MX2022011155A 2020-03-09 2021-03-09 Inmunización activa de refuerzo contra tétanos, difteria y tosferina. MX2022011155A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011010025 2020-03-09
IN202011055399 2020-12-19
PCT/US2021/021532 WO2021183533A1 (en) 2020-03-09 2021-03-09 Active booster immunization against tetanus, diphtheria and pertussis

Publications (1)

Publication Number Publication Date
MX2022011155A true MX2022011155A (es) 2023-01-04

Family

ID=77672117

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011155A MX2022011155A (es) 2020-03-09 2021-03-09 Inmunización activa de refuerzo contra tétanos, difteria y tosferina.

Country Status (12)

Country Link
US (1) US20230072809A1 (es)
EP (1) EP4117719A4 (es)
JP (1) JP2023517330A (es)
KR (1) KR20230011916A (es)
CN (1) CN115697389A (es)
AU (1) AU2021236055A1 (es)
BR (1) BR112022017973A2 (es)
CA (1) CA3174987A1 (es)
CL (1) CL2022002456A1 (es)
IL (1) IL296286A (es)
MX (1) MX2022011155A (es)
WO (1) WO2021183533A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512110A (pt) * 2004-06-15 2007-10-23 Idera Pharmaceutical Inc multìmeros de oligonucleotìdeos imunoestimulatórios
AU2007239095B2 (en) * 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2011143230A1 (en) * 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US9452212B2 (en) * 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
SG11201506858SA (en) * 2013-03-08 2015-09-29 Crucell Holland Bv Acellular pertussis vaccine
SG11201600709TA (en) * 2013-08-05 2016-02-26 Glaxosmithkline Biolog Sa Combination immunogenic compositions
EP3890770A4 (en) * 2018-12-05 2022-09-28 Sanofi Pasteur, Inc. PERTUSSIS BOOST VACCINE

Also Published As

Publication number Publication date
KR20230011916A (ko) 2023-01-25
US20230072809A1 (en) 2023-03-09
CN115697389A (zh) 2023-02-03
AU2021236055A1 (en) 2022-10-20
CL2022002456A1 (es) 2023-06-23
WO2021183533A1 (en) 2021-09-16
IL296286A (en) 2022-11-01
BR112022017973A2 (pt) 2022-11-16
EP4117719A1 (en) 2023-01-18
EP4117719A4 (en) 2024-05-22
JP2023517330A (ja) 2023-04-25
CA3174987A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
WO2003009812A3 (en) Use of glycosylceramides as adjuvants for vaccines against infections and cancer
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
EP1404363A4 (en) ADJUVANT COMPOSITION FOR MUCUSAL OR INJECTION VACCINES
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
AR092896A1 (es) Composiciones inmunogenicas
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
MX2022011155A (es) Inmunización activa de refuerzo contra tétanos, difteria y tosferina.
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2022011159A (es) Vacunas contra herpes zoster que comprende un agonista de tlr9.
EP4248992A3 (en) Foot-and-mouth disease vaccine
MX2022010642A (es) Vacunas contra coronavirus que comprenden un agonista de tlr9.
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
EP1467771A4 (en) MYCOBACTERIAL VACCINE
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
GB2444676A (en) Adjuvanted vaccine
MX2021005303A (es) Composiciones inmunogenicas.
EP1742656A4 (en) NEW EXTRACT OF SKIN OF CACAHUÈTE AS VACCINE ADJUVANT
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant